Colonoscopy, endoscopy, fecal calprotectin, CRP, imaging, intestinal ultrasound, and monitoring research.
Page 9 of 33 · 1559 articles
This trial tests several targeted therapies (including risankizumab) alone and in combination for adults with moderate to severe Crohn's disease, aiming to measure endoscopic remission and safety. Positive findings could...
Distinguishing colorectal cancer from IBD-related inflammatory thickening can be challenging but crucial for treatment decisions. If validated, DECT parameters could offer a noninvasive tool to improve diagnostic...
NPC can present with symptoms that overlap gastrointestinal, pulmonary, or psychiatric disorders and may be under-recognized. LysoSM-509 and HDL abnormalities may help prompt earlier diagnosis in diverse presentations.
Atypical presentations of Crohn's disease (abdominal wall abscess with enterocutaneous fistula) can delay diagnosis and treatment in children. Patients with communication difficulties may be at higher risk for missed or...
This study compares bloodstream infection risk across commonly used biologics for IBD, which could affect decisions about choosing or monitoring biologic therapy. It also highlights that steroid co-use may increase...
Dietary approaches that reduce gut inflammation could offer a low‑risk option to help manage symptoms and biomarkers in Crohn’s disease. This trial specifically tests a catered anti‑inflammatory diet and measures fecal...
Dose increases are common during IBD maintenance and vary a lot by drug and patient profile. Knowing which treatments and patient factors are linked to escalation can help patients and clinicians plan monitoring and...
Noninvasive fecal biomarkers are widely used to track IBD activity. Knowing whether different FC assays give comparable results and whether combining tests adds value affects how patients and clinicians interpret...
Malnutrition is common but under-recognized in ulcerative colitis; a simple, more sensitive screening tool could help clinicians find patients who need nutritional assessment and support earlier.
The study suggests ulcerative colitis shows greater mucosal immune variability across sex, age and severity than Crohn’s disease, which could affect how patients are grouped for research or future personalized...
If you have UC, bowel urgency may indicate active inflammation more reliably than some other symptoms. Recognizing urgency could help prompt timely objective testing and treatment decisions.
This study compares two commonly used biologics as first-line therapy for moderate-to-severe ulcerative colitis and reports better short- and long-term effectiveness for vedolizumab with similar safety. The results could...
Links between circulating adaptive receptors, coordinated immune programs, and short-term treatment-response signals could eventually enable blood-based immune biomarkers or patient stratification tools in IBD research...
The study suggests stromal fibroblasts can drive pro-inflammatory neutrophil programs in ulcerative colitis and that targeting fibroblast-associated pathways may reduce neutrophil-driven inflammation—information that...
A colon-targeted, enzyme-activated imaging probe could help distinguish early versus late inflammatory stages in IBD and provide a noninvasive fecal fluorescence signal—potentially improving disease monitoring beyond...
Depression before an IBD diagnosis was linked to more early treatment escalation and acute-care use after diagnosis. Recognizing preexisting depression could help clinicians identify patients who may benefit from closer...
Real-world registry data on upadacitinib can help patients and clinicians understand how the drug performs outside clinical trials, including patterns of use, effectiveness, and safety over time.
Identifies a fibroblast senescence signature and highlights ADAMTS2 as a candidate biomarker linked to inflammation and fibrosis in IBD, which could guide future diagnostic or therapeutic research relevant to Crohn’s...
A simple blood lymphocyte percentage could be a convenient, non-invasive marker to help distinguish endoscopic remission from active disease in both Crohn’s and ulcerative colitis; chemokines CXCL10 and CCL25 may also...
Postoperative recurrence is common after Crohn’s surgery; a reliable noninvasive test could reduce the need for early colonoscopy and help tailor follow-up.
The paper links specific gut bacteria, inflammatory cytokines, and two microRNAs with UC activity, which could point toward new diagnostic biomarkers or targets for research into disease mechanisms.
Non-invasive imaging biomarkers that track intestinal inflammation and structure could speed preclinical testing of IBD therapies and guide translational imaging research relevant to clinical monitoring of ulcerative...
This study compares two JAK inhibitors (upadacitinib and tofacitinib) used as rescue therapy for acute severe ulcerative colitis and reports lower 1‑year colectomy rates with upadacitinib. That could influence choices...
Trial design affects how quickly and reliably new IBD treatments are tested and approved, and can influence patient experience (placebo exposure, retention) and whether trial populations reflect real-world patients.
The study documents substantial increases in Crohn’s disease and ulcerative colitis prevalence and changing incidence patterns in Northeastern Italy from 2012–2024, which may affect healthcare demand and resource...
Identifying a genetic cause (XIAP frameshift variant) helped explain why anti‑TNF drugs failed and why blocking IL‑12/23 with ustekinumab led to improvement; that connection could influence treatment choices for similar...
Automated, validated grading of UC on colonoscopy images could reduce variability between endoscopists and help standardize severity assessment that influences treatment planning.
Early prediction of who will not respond to infliximab could help clinicians avoid prolonged ineffective treatment, enabling earlier reassessment and changes in therapy as part of treat-to-target care.
IL-23 inhibitors are a newer class of biologics for moderate-to-severe ulcerative colitis that may offer another effective option for patients who have not responded to existing therapies, with improving evidence for...
Patients and clinicians often need evidence about whether switching from ustekinumab to an anti‑TNF (infliximab or adalimumab) still gives meaningful clinical responses. This study suggests many patients can respond, but...
Obese patients with FibroScan-detected steatosis in this cohort had a high frequency of colitis and some cases of IBD, dysplasia, and cancer, which could affect screening and symptom evaluation decisions.
Refractory IBD in children is linked to growth and development problems, hospitalizations, and surgery; knowing treatment options after anti‑TNF failure matters for long‑term outcomes. The review highlights which...
HBV reactivation is a preventable but serious complication of chemotherapy and immunosuppression; this study shows low awareness and screening in Belgian specialists, suggesting patients starting immunosuppression may be...
FDA IND clearance lets PALI‑2108 move into a Phase 2 trial in Crohn’s disease, meaning the drug’s safety and efficacy will be formally tested in people with moderate-to-severe disease. The program is being run alongside...
Fatigue is extremely common in IBD and is closely linked to depression—recognizing and addressing mental-health issues may be important for patients who report significant fatigue.
Based on the title and source metadata, this appears to be a clinical study related to Crohn's disease, Inflammatory bowel disease, and CRP. The original article is from Journal of medical biochemistry.
This study directly compares two rescue medications used when intravenous steroids fail in acute severe ulcerative colitis, reporting similar short-term remission and safety but a slower early response with tacrolimus —...
This study gives real-world 52‑week data on upadacitinib maintenance in children with refractory Crohn's disease, showing meaningful remission rates but also notable adverse events. That balance is important for families...
Orofacial granulomatosis often co-occurs with Crohn's disease and appears linked to a distinct Crohn's phenotype and treatment needs. The findings suggest that advanced therapies can be effective for OFG-associated CD...
FDA clearance lets Palisade start a Phase 2 trial of PALI-2108 in moderate-to-severe Crohn’s disease, which could matter to patients and clinicians watching new oral treatments targeted to the lower intestine.
Based on the title and source metadata, this appears to be an opinion or commentary related to Crohn's disease, Inflammatory bowel disease, and Biomarkers. The original article is from Digestive and liver disease :...
Distinguishing Crohn’s disease from intestinal tuberculosis is a frequent problem in TB-endemic areas; a validated mobile ML tool could help clinicians make more accurate, faster diagnostic decisions and avoid...
A new oral investigational drug (TP317) is entering a Phase 1b study in adults with active UC to assess safety and pharmacokinetics, which may be relevant to patients seeking information about emerging therapies.
Microbial amino-acid metabolites may be active players in IBD biology and could become useful biomarkers or therapeutic targets. Understanding these metabolites helps explain links between the microbiome, immune...
Strictures cause obstructive symptoms and repeat surgery in Crohn’s disease; endoscopic options can relieve obstruction and potentially avoid or postpone surgery for some patients.
If disease activity hurts quality of life partly through low self-efficacy and (for UC) psychological distress, then boosting self-management confidence and identifying anxiety/depression could help improve...
A blood biomarker that flags higher risk for complicated Crohn's could help identify people who may need closer monitoring or earlier treatment escalation before clear symptoms or endoscopic inflammation appear.
Biologics can be critical for treating moderate-to-severe IBD, but cost and treatment failure limit access and long‑term use in this Indian cohort. Understanding uptake and reasons for stopping helps target interventions...
